Apellis Pharmaceuticals Inc (FRA:1JK)
€ 36.59 -0.37 (-1%) Market Cap: 4.53 Bil Enterprise Value: 4.33 Bil PE Ratio: 0 PB Ratio: 18.22 GF Score: 49/100

Apellis Pharmaceuticals Inc at Bank of America NAPA Healthcare Conference Transcript

Jun 16, 2021 / 08:30PM GMT
Release Date Price: €48.4 (-12.79%)
Tazeen Ahmad
BofA Securities, Research Division - VP

Okay. Good afternoon, everyone. Thanks for continuing to join us at the Bank of America Virtual Napa Conference. I'm Tazeen Ahmad. It is my pleasure to have our next presenting company, Apellis. For the next 50 minutes, we'll be talking about all the exciting things that have happened, and we expect to happen for the company. Speaking for the company this afternoon will be Co-Founder, CEO and President, Cedric Francois; Chief Financial Officer, Tim Sullivan; and of course, Adam Townsend, who's Chief Commercial Officer.

So gentlemen, good afternoon. Thanks so much for joining us.

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Good afternoon. It's wonderful to be here, Tazeen. Thank you for inviting us.

Tazeen Ahmad
BofA Securities, Research Division - VP

So you've had some good news happen recently. Why don't you maybe start off, Cedric, with giving us a quick overview of the company, your recent approval? And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot